Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma
暂无分享,去创建一个
J. Xu | Xuelei Ma | Jing Zhang | Jiaming Liu | Chenjing Zhu | Qingfang Li | Qisi Lian | Jing Xu
[1] Lamia AlHajri,et al. The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review , 2017, Journal of cardiovascular pharmacology and therapeutics.
[2] R. Millikan,et al. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. , 2016, European urology.
[3] S. Culine,et al. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter? , 2016, European journal of cancer.
[4] A. Bergman,et al. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin , 2016, World Journal of Urology.
[5] Frédérique Penault-Llorca,et al. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer? , 2015, Critical reviews in oncology/hematology.
[6] A. Bryant,et al. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. , 2015, The Cochrane database of systematic reviews.
[7] K. Tabata,et al. Comparison of radical cystectomy and chemoradiotherapy in patients with locally advanced bladder cancer. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[8] S. Steinberg,et al. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. , 2014, Urologic oncology.
[9] P. Kantoff,et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] S. Boorjian,et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Witjes,et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.
[12] S. Barni,et al. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. , 2014, European urology.
[13] M. Dimopoulos,et al. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Petra Macaskill,et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. , 2012, European journal of cancer.
[15] T. Powles,et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle‐invasive transitional cell carcinoma of the bladder , 2012, Cancer.
[16] S. Culine,et al. Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. , 2012, European journal of cancer.
[17] C. Miller,et al. Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases , 2011, Breast Cancer Research.
[18] F. Penault-Llorca,et al. Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer , 2010, British Journal of Cancer.
[19] Karin Haustermans,et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. , 2010, The Lancet. Oncology.
[20] G. Sonpavde,et al. Treatment of metastatic urothelial cancer: opportunities for drug discovery and development , 2008, BJU international.
[21] M. Galsky,et al. Phase II trial of dose‐dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function , 2007, Cancer.
[22] D. Slamon,et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Sergio Ricci,et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] L. Collette,et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] S. Groshen,et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A R Jadad,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.
[27] H. Stähelin. Guidelines , 1994, Communicating Science.
[28] C. Sternberg,et al. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] A. Jemal,et al. Global Cancer Statistics , 2011 .
[30] L. Collette,et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. , 2006, European journal of cancer.
[31] E. Eisenhauer,et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). , 2005, Journal of the National Cancer Institute.
[32] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.